Your SlideShare is downloading. ×
  • Like
  • Save
Rad onc presentation
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Rad onc presentation

  • 1,579 views
Published

 

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
1,579
On SlideShare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
2

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Radiation Oncology 101Sewit Teckieteckies@mskcc.orgChief Resident, Department of Radiation OncologyMemorial Sloan-Kettering Cancer Center, New York, NYNote: The following material is intended for MSKCC internal medicine housestaff teaching purposesonly. The slides are courtesy of Dr. Sewit Teckie and were updated for the LibGuide in 2012-2013.
  • 2. Categories of RadiationExternal beam radiation (EBRT) Brachytherapy
  • 3. Physics• Electrons• Superficial treatments i.e.skin• Photons• IMRT• Protons• Optimal dosimetry• Not available at MSKCC• Neutrons
  • 4. RadiobiologyX-ray photonFree radicalDouble strand breakCell death Mitotic Apoptotic
  • 5. Terminology• Conventional: 2-dimensional• 3DCRT: 3-Dimensionalconformal RT• IMRT: Intensity ModulatedRadiation Therapy• IGRT: Image Guided RadiationTherapy• SRS: Stereotactic Radiosurgery• SBRT: Stereotactic Body RTAP FieldIMRT
  • 6. Treatment ProcessPatient seen in consultSimulation (CT or PET/CT)Treatment planningSet-upTreatment Start1 week1 week1 day
  • 7. Simulation• CT or PET/CT scan• Immobilization• Isocenter placement• Tattoo the patientH&N MaskPatient Marking
  • 8. Treatment Planning:Contouring• Contouring• Normal tissue• Tumor• Terminology• GTV: Gross tumor volume• CTV: Clinical target volume• PTV: Planning target volume
  • 9. Treatment Planning: TargetDelineation• GTV: Volume encompassing grossly visible tumor• CTV: Volume to account for uncertainties in suspectedmicroscopic spread• PTV: Volume to account for geometric and other non-biologic uncertaintiesGTVGTV CTV PTV
  • 10. Treatment Planning: TargetCoverageTarget volume• Dose-Volume Histogram
  • 11. Treatment Planning: PlanReviewAbide by set dose constraints for normal tissues:DVH
  • 12. Treatment Start: PatientSet-UpDRR / Sim film Portal film
  • 13. Patient Set-Up: IGRT
  • 14. Dose & Fractionation• Dose expressed in Gray, Gy (1 J/Kg)• Fractionation = # of treatments• Hypofractionation• Larger dose per fraction• Fewer total number of treatments• Hyperfractionation• Smaller dose per fraction• Increase total number of treatments
  • 15. Sites & DosesSite Dose (Gy) FractionsBreast 50-60 30Prostate 86 48Brain Tumor (Primary) 60 30H&N 70 33Rectal 50 28Post-Operative 50-60 30Palliative 30 10
  • 16. Breast Cancer• Prone vs. Supine• Breast alone vs. Breast + nodes• Post-mastectomy• Dose/Fractionation• 60 Gy / 30 - Standard• 52.4 Gy / 20 - CanadianTangents
  • 17. Prostate Cancer• Brachytherapy• Seeds alone – Iodine• HDR treatment (temporaryimplants) - Iridium• EBRT• 86.4 Gy / 48 fractions• Prostate/SV alone +/- nodes• Hormone therapy• Combination Therapy• Seeds + EBRTIMRT
  • 18. Seminoma: Stage I• Observation ~16% relapse• Target the pelvic andparaaortic lymph nodes• 25.5 Gy / 17 fractionsDog Leg Field
  • 19. GBM• Post-operative cavity• Fuse MRI with our CT scanto delineate edema andcontrast enhancement• 60 Gy concurrent withTemodarIMRT
  • 20. H&N Cancer: Subsites• Pharynx:• Oropharynx• Nasopharynx• Hypopharynx• Nasal cavity / Paranasalsinuses• Oral cavity• Larynx• Salivary glands• Thyroid
  • 21. H&N Cancer• Gross tumor, positivelymph nodes, and lymphnodes at risk• PET/CT simulation• Concurrent Cisplatin orCetuximab• 70 Gy / 33 fractionsTonsil Cancer
  • 22. Lung Cancer: SBRT• SBRT (Stereotactic BodyRadiation)• Early stage non-operable,peripheral cancers• 12 Gy x 4 or 9 Gy x 5 or 18Gy x 3“No Fly Zone”
  • 23. Lung Cancer: SBRTTime (seconds)IGRT
  • 24. Lung Cancer: SBRTTime (seconds)MarkerDisplacement(cm)Stereoscopic infra-redcameraMarker Locations- Left chest- Right chest- BellyRespiratory Gating
  • 25. Hodgkin Lymphoma: DosesDoses:• Early stage disease/PET neg 20 Gy• Unfavorable early stage (bulky): 30 Gy• Stanford V: All sites equal to or greaterthan 5cm: 36 Gy
  • 26. Hodgkin Lymphoma: Fields1995 – Involved-Field Radiotherapy(IFRT)1970 – TotalLymphoid Irradiation(TLI)2008 – InvolvedNode Radiotherapy(INRT)
  • 27. Hodgkin Lymphoma: FieldsMantle Neck Mediastinum
  • 28. Non-Hodgkin LymphomaDoses:• MALT: 30 Gy• DLBCL:• Pet negative: 180 cGy x 17• Uncertain response: 180 cGy x 25• Follicular lymphoma• Boom-Boom: 200 cGy x 2• Definitive: 24-30 Gy / If bulky 36 Gy
  • 29. Stomach MALT: 4D-CTSimulation
  • 30. Treatment Plan3000 cGy
  • 31. TBI & Transplant• AML pre-transplant• Doses: 13.75 Gy / 11 fractions• 3 / 3 / 3 /2 fractions per dayAP PA
  • 32. Extramedullary LeukemiaLeukemia Cutis: TSEB 24 GyGranulocytic sarcoma: 24 Gy
  • 33. Palliation: Brain MetsWBRT:• >3 brain mets• Opposed lateral fields• 30 Gy / 10 fractions
  • 34. Palliation: Brain MetsSRS:• 1-3 Mets• Less than 3 cm• 18-24 Gy in a single fraction• Simulation, planning, &treatment in one dayHead frame
  • 35. Palliation: Cord CompressionConventional RT:• AP/PA• Vertebral levelsinvolved + 1 aboveand 1 below• 30 Gy / 10fractions
  • 36. Palliation: Cord CompressionIGRT:• Re-treatments &radioresistanthistologies• 18-24 Gy definitiveor post-op• Conformal planGTV
  • 37. Palliation: Bone metsConventional RT:• AP/PA• 3 Gy x 10 fractionsor 8 Gy x 1 fractionPET
  • 38. Chemo-RT• Definitive/curative: Head and neck,locally advanced lung, brain, GI, Gyn,bladder• Post-operative: Head and neck, lung,brain, GI, Gyn• Pre-op: for tumor downstaging
  • 39. Major Acute Toxicities<90 days post RTRT Site Major Acute ToxicitiesBreast Skin: dry and moist desquamationProstate Urinary: frequency, urgency, obstructionGI/Rectal: Diarrhea, loose stoolsBrain Nausea, fatigue, hair lossGI Diarrhea, rectal painH&N Mucositis, xerostomia, loss of taste, skinBone /SpineMetsMarrow suppression if field is large enoughAll patients Fatigue
  • 40. Sub-Acute Toxicities• Lung: Pneumonitis (6 wks post RT)• Skin: Radiation recall• Occur months to years after radiation treatment• Follows recent administration of a chemotherapeuticagent• Occurs with the prior radiation port, characterized byfeatures of radiation dermatitis• Brain: fatigue, sluggishness, and mildneurocognitive effects
  • 41. Late Toxicities>6 months post RTRT Site Major Acute ToxicitiesBreast Cosmetic changes (skin, implants)Heart disease (minimized with modern planning techniques)Prostate UrinaryImpotencyRectalBrain Radiation necrosisH&N Xerostomia, skin changes, hearing
  • 42. Secondary Malignancy• Occur in or adjacent to the field of radiation• Latency of 7+ years for solid tumors• Earlier for leukemias• Type of secondary malignancy is dependenton site and tissue initially irradiated• Breast: Sarcoma• HL: Breast (in females)• Prostate: Bladder, colon, sarcoma• Absolute risk is small ~ 1%
  • 43. Follow-up• Typically see patients back 1 month followingtreatment• Follow-up is integrated between medicaloncology and surgical oncology• Length of follow-up is a function of disease
  • 44. Summary• How radiation works• Types of radiation therapy• How we contour and plan RT• Diseases we treat with radiation therapy• Dose and fractionation• Acute and long-term side effects
  • 45. Questions??